---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093932"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:05:23.309853+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IN8bio receives Nasdaq minimum bid price deficiency notice; Q2 net loss $8.6M, cash $10.2M

## Summary
- Nasdaq notified IN8bio on Aug 6, 2024 that bid price closed below $1.00 for 31 consecutive days; 180-day compliance period to Feb 3, 2025.
- Q2 2024 net loss of $8.6M ($0.19 per share) vs net loss of $7.7M ($0.27) in Q2 2023.
- Cash and cash equivalents totaled $10.2M as of June 30, 2024, down from $21.3M at Dec 31, 2023.
- Phase 1 INB-100 data: 100% 1-year complete remission in evaluable patients; two patients relapse-free over 3.5 years.
- Phase 1 INB-200: 92% of GBM patients exceeded median PFS of 7 months; no cell therapy-related toxicities observed.

## SEC filing metadata
- accession: 0000950170-24-093932
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000095017024093932/0000950170-24-093932-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000095017024093932/inab-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093932
- JSON: https://secwatch.observer/filing/0000950170-24-093932.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093932.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.